Oramed Pharmaceuticals Inc.Find Ratings Reports
ORAMED PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. ORAMED PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 9.88 which clearly shows the ability to cover any short-term cash needs. ORMP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 58.24% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||0.68||0.68|
|Net Income ($mil)||-2.28||-4.07|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||40.83||26.19|
|Total Assets ($mil)||46.16||37.43|
|Total Debt ($mil)||0.09||0.0|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||-333.48||-597.95|
|Return on Assets||-23.38||-40.07|
|Return on Equity||-31.64||-69.58|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||23.28||17.38|
|Div / share||0.0||0.0|
|Book value / share||1.47||1.24|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||158858.0||126971.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 2.20 indicates a significant discount versus the S&P 500 average of 3.92 and a significant discount versus the subsector average of 8.34. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, ORAMED PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives.
|ORMP NM||Peers 28.34||ORMP NM||Peers 20.82|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ORMP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ORMP's P/CF is negative making the measure meaningless.
|ORMP NM||Peers 17.94||ORMP NA||Peers 2.21|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ORMP 2.20||Peers 8.34||ORMP 32.19||Peers 27.15|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ORMP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ORMP is expected to have an earnings growth rate that exceeds its peers.
|ORMP 27.74||Peers 7.85||ORMP 2.69||Peers 34.65|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ORMP is trading at a significant premium to its subsector.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
ORMP significantly trails its peers on the basis of sales growth.